Contipro
Contipro is a Czech pharmaceutical and biotechnology company founded in 1990 that researches, produces, and sells hyaluronic acid-based products including pharmaceutical active ingredients, medical devices, cosmetic ingredients, dietary supplements (Geloren), veterinary products, and proprietary nanofiber production equipment (4SPIN).
- Company typePrivate
- Founded1990
- HeadquartersDolni Dobrouc, Czechia
- Headcount101–250
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Contipro does
Contipro a.s. is a privately-held Czech pharmaceutical and biotechnology company founded in 1990 and headquartered in Dolní Dobrouč. The company specializes in the research, development, and production of hyaluronic acid (HA) and HA-based products, operating across pharmaceutical active ingredients, medical devices, cosmetic raw materials, dietary supplements, veterinary applications, and nanofiber production equipment. Nearly half of its 101-250 employees work in R&D, supported by state-of-the-art laboratories spanning several thousand square meters, and the company states it is among the world's leaders in HA research and production.
Core technology centers on biotechnological production of high-purity sodium hyaluronate via bacterial fermentation of Streptococcus zooepidemicus, free of animal-derived materials and pathogens, with molecular weight options spanning 7 kDa to 2,300 kDa. The proprietary 4SPIN platform produces organized nanofibers from HA and other polymers through electrostatic spinning at semi-industrial scale, with built-in safety features. Manufacturing operates under GMP (ICH Q7) certification, has been FDA-audited, holds Certificates of Suitability to the European Pharmacopoeia from EDQM, and has a Drug Master File filed with the FDA. The company holds multiple patents and utility models and launches 2-4 new products per year.
Contipro generates revenue through B2B sales of pharmaceutical-grade sodium hyaluronate and cosmetic raw materials to manufacturers globally, finished medical devices (including the Sicalm HA dental tamponade), branded consumer products under the Geloren joint-health line sold via a dedicated e-commerce storefront, and hardware sales of 4SPIN nanofiber equipment to research institutions and industrial customers. Distribution is handled through direct B2B sales and international distribution networks serving Europe, North America, and Asia-Pacific, with quote-based pricing and multi-year contracts on the API side. Revenue is not publicly disclosed. R&D is supported by an extensive portfolio of EU and Czech government grants funding active projects in nanobiotechnology, biomaterials, stem cells, neurodegenerative disease treatments, wound healing devices, and new HA forms.
Contipro firmographics
Firmographics- Name
- Contipro
- Legal name
- Contipro a.s.
- Website
- https://contipro.cz
- Company type
- Private
- Founded year
- 1990
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Contipro is a Czech pharmaceutical and biotechnology company founded in 1990 that researches, produces, and sells hyaluronic acid-based products including pharmaceutical active ingredients, medical devices, cosmetic ingredients, dietary supplements (Geloren), veterinary products, and proprietary nanofiber production equipment (4SPIN).
- Ownership category
- akta.pro rank
Contipro industry classification
Industry- Product category
- Pharmaceutical Biotechnology
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)
- akta.pro secondary industries
- Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Nutraceuticals & Functional Ingredients for Animal Diets (Probiotics, Omega-3, Joint, GI) (HLAMAHAH)
Keywords
Where Contipro is headquartered
LocationHeadquarters
- HQ city
- Dolni Dobrouc
- HQ country
- Czechia
- HQ region
- Europe
Offices1 record
Markets served
Contipro business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Active Ingredients (API): Sale of high-purity hyaluronic acid as active pharmaceutical ingredient to pharmaceutical manufacturers. Products include sodium hyaluronate in various molecular weights (HMW 250-2300 kDa, LMW 7-250 kDa) for pharmaceutical applications.
- Medical Devices: Development and sale of medical devices based on hyaluronic acid including wound healing products, ophthalmic surgery applications, and dental products like Sicalm HA.
- Branded Consumer Products: Sale of branded products including Geloren dietary supplements for joint health and veterinary products under the same brand.
- Cosmetic Raw Materials: Supply of anti-aging substances including hyaluronic acid, peptides, and other cosmetic ingredients to cosmetics manufacturers.
- Nanotechnology Equipment: Sale of 4SPIN devices for nanofiber production to research institutions and industrial customers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Sodium Hyaluronate HMW (High Molecular Weight) |
| Other | Multi-year contract | Sodium Hyaluronate LMW (Low Molecular Weight) |
| Other | Multi-year contract | Oligosaccharides |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Contipro product offering
Product offeringCore offering
Contipro biotechnologically produces pharmaceutical-grade hyaluronic acid (sodium hyaluronate) via bacterial fermentation of Streptococcus zooepidemicus and sells it as an active pharmaceutical ingredient to drug manufacturers. The company also develops and sells medical devices based on hyaluronic acid (wound healing, dental), anti-aging cosmetic raw materials, the proprietary 4SPIN nanofiber production equipment, the Geloren branded joint nutrition supplement line for humans and animals, and customized hyaluronan derivatives and specialities.
Product overview
Contipro is a Czech pharmaceutical and biotechnology company (founded 1990) specializing in hyaluronic acid research and production. The company operates on three pillars: active pharmaceutical ingredients (API), modern technical equipment, and innovative final products. Its product portfolio includes pharmaceutical-grade sodium hyaluronate (produced via bacterial fermentation), the proprietary 4SPIN nanofiber production technology, medical devices including Sicalm HA dental products, the Geloren food supplement and veterinary product line, anti-aging cosmetic ingredients, and custom hyaluronan derivatives. Research and development is central to the business, with approximately half of employees dedicated to R&D activities in state-of-the-art laboratories.
Differentiator
Problem solved
Functional benefit
Brands
- Geloren: Joint health dietary supplement product line for humans and animals
- 4SPIN
- Fybich
- Institut
Products and services
- Sodium Hyaluronate (Pharmaceutical Grade)
Quantifiable outcome
- Products stable for 36 months at recommended storage conditions (2-8°C)
- +1 more outcomes
Companies that use Contipro
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles5 records
Contipro technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Contipro partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Family Business Network CzechmoderateContipro became a proud member of Family Business Network Czech in 2023, connecting with other family-owned businesses in the region.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Contipro competitors and assessment
Company assessmentEmerging players
- Novonesis (formerly Novozymes): Global biotechnology leader in industrial enzymes and microbial fermentation, with growing exposure to biopolymers including hyaluronic acid via partnerships. Comparable in fermentation process technology and biotech manufacturing capabilities, though not a direct HA competitor.
- Crown Laboratories: US-based specialty skincare and aesthetics company with a portfolio including HA-based dermal fillers and skincare products. Comparable as a downstream consumer of HA technology focused on aesthetics and dermatology end-markets.
Broad incumbents
- Galderma: Global dermatology-focused pharma with a strong aesthetics and skincare portfolio, including injectable HA-based fillers. Comparable as a downstream consumer of HA technology in dermatology and aesthetics, though not a primary HA manufacturer.
- Evonik Industries: Global specialty chemicals giant with a portfolio that includes HA production for medical and cosmetic applications via its Health Care business line. Comparable as a fermentation-based HA supplier but operating at much broader portfolio and scale.
- LG Chem (Life Sciences): Korean chemical conglomerate with a Life Sciences division producing HA APIs and biosimilar products for global markets. Comparable as a large-scale fermentation-based HA manufacturer supplying pharmaceutical and cosmetic markets.
Direct peers
- Seikagaku Corporation: Japanese specialty pharma built around glycosaminoglycan chemistry (including hyaluronic acid) for joint injection therapies and ophthalmic viscosurgical devices. Comparable in API science, molecular-weight specialization, and indication focus.
- Fidia Farmaceutici: Italian specialty pharma focused on HA-based products for joint health (viscosupplementation), ophthalmology, and wound care. Comparable as a vertically integrated HA-based pharmaceutical and medical device company selling into overlapping indications.
- Anika Therapeutics: US-listed specialty medical device company developing HA-based intra-articular, ophthalmic, and regenerative products (e.g., Monovisc, Cingal, Hyalofast). Comparable as a hyaluronic-acid-based therapeutic and regenerative medicine company.
- Bloomage Biotech: The world's largest hyaluronic acid producer, with end-to-end coverage from raw material fermentation to branded skincare and medical aesthetics products. Directly comparable to Contipro across pharma-grade HA APIs, medical-aesthetics applications, and cosmetic ingredients.
Others
- Sanofi (Genzyme/Synvisc franchise): Global pharmaceutical major that markets HA-based intra-articular injection products (e.g., Synvisc/Synvisc-One) through its specialty care franchise. Comparable as a downstream competitor in HA-based joint therapies, though operating as a broad pharmaceutical incumbent rather than a HA specialist.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Contipro social profiles
Digital presenceContipro compliance and trust
Trust signalCompliance5 records
Contipro financial estimates
Financial estimateRevenue estimate
Valuation estimate
Contipro leadership team
Management profileNumber of profiles
Contipro funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Contipro M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Contipro
What does Contipro do?
Contipro biotechnologically produces pharmaceutical-grade hyaluronic acid (sodium hyaluronate) via bacterial fermentation of Streptococcus zooepidemicus and sells it as an active pharmaceutical ingredient to drug manufacturers. The company also develops and sells medical devices based on hyaluronic acid (wound healing, dental), anti-aging cosmetic raw materials, the proprietary 4SPIN nanofiber production equipment, the Geloren branded joint nutrition supplement line for humans and animals, and customized hyaluronan derivatives and specialities.
Is Contipro a public or private company?
Contipro is a private company. It is classified as family owned and is currently operating.
When was Contipro founded?
Contipro was founded in 1990. It employs 101 to 250 people.
Where is Contipro based?
Contipro is headquartered in Dolni Dobrouc, Czechia, in the Europe region.
How does Contipro make money?
Five revenue lines are on record. Pharmaceutical Active Ingredients (API) is the primary driver. The others are medical Devices, branded Consumer Products, cosmetic Raw Materials and nanotechnology Equipment.
Who are Contipro's main competitors?
Emerging players on record are Novonesis (formerly Novozymes) and Crown Laboratories. Broad incumbents are Galderma, Evonik Industries and LG Chem (Life Sciences). Direct peers are Seikagaku Corporation, Fidia Farmaceutici, Anika Therapeutics and Bloomage Biotech. Sanofi (Genzyme/Synvisc franchise) is listed as an others.
Does Contipro have an API?
No public API is recorded for Contipro.
What industry is Contipro in?
Contipro's product category is Pharmaceutical Biotechnology. Its primary akta.pro industry code is EUAAAIAK, Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives, with a secondary code of HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its NAICS code is 325414 and its SIC code is 2834.